Page 10 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $2.31
52wk Low $0.59 Atossa Therapeutics, Inc. ATOS $1.66
107 Spring Street
Seattle, WA 98104

(USD - in millions) atossatherapeutics.com
Market Cap 208.0
Enterprise 119.5
Basic Shares Out. 125.30 COMPANY OVERVIEW
Float 117.48
Institutional Holdings 13.05% Detailed Analysis:Channelchek.com
Short Interest 10.56
Avg. 90-Day Volume 1.48 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing innovative medicines in areas of significant unmet
medical need in oncology with a focus on using (Z)-endoxifen to
prevent and treat breast cancer.
EPS Data
2021 2022 2023
CQ1 (0.04) (0.04) (0.05)
CQ2 (0.06) (0.05) (0.08)

CQ3 (0.04) (0.06) (0.05)
CQ4 (0.04) (0.06) (0.06)
CY (0.18) (0.21) (0.24) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.73
ROE (ttm) -28.80
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
107 Spring StrSeattle WA 98104

Key Executives
CEO: Quay, Steven
CFO: Rees, Heather
COO: N/A
IR: Van Zanten, Eric
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures